Education
About Us
Working with TipRanks
Follow Us
Jorge Santos da Silva Insider Profile
4 Followers
Jorge Santos da Silva, CEO, Director at MoonLake Immunotherapeutics, holds 0.00 shares in MoonLake Immunotherapeutics (Ticker: MLTX).
Jorge Santos da Silva has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Jorge Santos da Silva does not currently own shares as a corporate insider.
A breakdown of Jorge Santos da Silva's holdings
Insider Roles
CEO, Director
Roles that Jorge Santos da Silva holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Dec 10, 2025 - Today
Return:+8.30%
The most profitable trade made by Jorge Santos da Silva
Jorge Santos da Silva's Trading History
List of latest transactions for each holding click on a transaction to see Jorge Santos da Silva's performance on stock
You May Also Like
Jorge Santos da Silva insider profile FAQ
What is the percentage of profitable transactions made by Jorge Santos da Silva?
The percentage of profitable transactions made by Jorge Santos da Silva is ―.
What is the average return per transaction made by Jorge Santos da Silva?
The average return per transaction made by Jorge Santos da Silva is ―.
What stocks does Jorge Santos da Silva hold?
Jorge Santos da Silva holds: MLTX stocks.
What was Jorge Santos da Silva’s latest transaction?
Jorge Santos da Silva latest transaction was an Uninformative Buy of ―.
What was Jorge Santos da Silva's most profitable transaction?
Jorge Santos da Silva’s most profitable transaction was an Informative Sell of MLTX stock on December 10, 2025. The return on the trade was 8.30%.
What is Jorge Santos da Silva's role in MoonLake Immunotherapeutics?
Jorge Santos da Silva's role in MoonLake Immunotherapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.